Current Status and Perspectives from Epidemiological and Clinical Research on Cancer Survival and Outcome – Webinar recording – IARC-ESMO Cancer Prevention Learning and Capacity-Building Initiative

Current Status

Not Enrolled

Price

Free

Get Started

What is the current status of research on cancer survival worldwide?

Which data are needed to better inform policies, and which data are missing?

How could we collect better data on survival and quality of life of patients with cancer?

Watch the recording from the IARC-ESMO webinar held on 1 July 2024 to find out.

CHAIR AND SPEAKER

Dr Isabelle Soerjomataram

Deputy Head, Cancer Surveillance Branch

International Agency for Research on Cancer (IARC)

About Dr Isabelle Soerjomataram

RESEARCH ON CANCER SURVIVAL FOR IMPROVED CANCER OUTCOMES: WHICH DATA ARE NEEDED, AND WHICH DATA ARE MISSING?

Dr Isabelle Soerjomataram will present the global status of cancer survival and the availability of data to better inform policies to reduce premature mortality from cancer worldwide.

SPEAKERS

CANCER SURVIVAL – A PERSPECTIVE FROM LOW- AND MIDDLE-INCOME COUNTRIES

Professor Rajaraman Swaminathan

Professor and Head, Department of Epidemiology, Biostatistics and Cancer Registry
Cancer Institute (WIA)
India

Cancer survival data from low-and middle-income countries are on the rise in recent times with international collaborative initiatives. The main impediment is the completeness of follow-up data, especially mortality ascertainment. Active follow-up methods have improved data quality by quantifying the bias in estimation. Long-term hospital-based survival data have been useful to correlate treatment milestones. Cancer survival statistics are an essential component of surveillance for effective control of the disease.

Short biography: Professor Rajaraman Swaminathan

Professor Rajaraman Swaminathan is presently serving as a Professor and Head of the Department of Epidemiology, Biostatistics and Cancer Registry at the Cancer Institute (WIA), Chennai, India, as well as its Associate Director. His areas of specialization are survival analysis, cancer registration, and preventive oncology. Professor Swaminathan holds two doctoral degrees: a PhD in Statistics from the University of Madras, India (2002) and a PhD with honours in Epidemiology from Tampere University, Finland (2012). His field of training encompasses both descriptive and analytical epidemiology. His postdoctoral research work was on differential cancer survival based on 0.62 million patients in 14 countries, survival methods under non-random censoring, and evaluation of cancer screening programmes through registry data at the International Agency for Research on Cancer (IARC). He has been an editor of three IARC Scientific or Technical Publications, and an author or co-author of 130 other publications in scientific journals or monographs.

CANCER SURVIVAL AND SURVIVORSHIP IN HIGH-INCOME COUNTRIES – BEYOND THE REDUCTION OF MORTALITY RATES

Dr Inès Vaz-Luis

Oncologist, Breast Cancer Committee, Gustave Roussy
Head, Cancer Survivorship Group, INSERM 981
Research Director, Department for the Organization of Patient Pathways, Gustave Roussy

France

Currently, approximately two third of patients with cancer live for more than 5 years after receiving the diagnosis. There are an increasing number of people living beyond a cancer diagnosis, and currently it is estimated that there are more than 12 million cancer survivors in Europe. Dr Inès Vaz-Luis, MD, MSc, PhD, will review data and research on cancer survival in high-income countries, as well as the physical and psychosocial challenges faced by patients with cancer and survivors from the diagnosis of cancer through active treatment and beyond. She will also reflect on how health information systems could be transformed to collect better data on survival and quality of life of patients with cancer.

Short biography: Dr Ines Vaz-Luis

Dr Inès Vaz-Luis is a medical oncologist and clinical researcher focused on breast cancer survivorship. In 2016, she moved to Gustave Roussy to build an innovative survivorship-focused clinical and research group, which has dozens of researchers and has now translated into an institutional programme focused on survivorship.
Dr Vaz-Luis leads several national efforts focused on quality of life (QOL) in cancer, she co-chairs the scientific development of the CANcer TOxicities (CANTO) cohort (NCT01993498), and she is leading the development of a national digital platform to accelerate QOL research in France (weSHARE-ESR-EquipEx+). She is often an invited speaker at major scientific conferences, including conferences of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO), European Breast Cancer Conferences (EBCC), and the St. Gallen International Breast Cancer Conference. She is an executive board member of the Breast International Group (BIG). In 2024, she was awarded the ASCO International Women who Conquer Cancer Mentorship Award. During recent years, her research has focused on risk stratification of breast cancer-related toxicities and on building interventions to mitigate the deterioration of QOL in the after-cancer phase.

Organized with the support of and in collaboration with the European Society for Medical Oncology (ESMO).

CONTENT

To access the content: 1) login / register to the platform; 2) click on the “Enrol” button. The page will refresh and you will be able to click on the card below.

Webinar recording – Current Status and Perspectives from Epidemiological and Clinical Research on Cancer Survival and Outcome

Watch the recording

Resource Content

Webinar recording – Current Status and Perspectives from Epidemiological and Clinical Research on Cancer Survival and Outcome